nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—asthma—chronic obstructive pulmonary disease	0.625	1	CtDrD
Montelukast—CYP2A6—Formoterol—chronic obstructive pulmonary disease	0.0636	0.255	CbGbCtD
Montelukast—CYP2A6—Arformoterol—chronic obstructive pulmonary disease	0.0636	0.255	CbGbCtD
Montelukast—CYP2A6—Prednisolone—chronic obstructive pulmonary disease	0.0283	0.114	CbGbCtD
Montelukast—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0219	0.0878	CbGbCtD
Montelukast—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0219	0.0878	CbGbCtD
Montelukast—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0168	0.0674	CbGbCtD
Montelukast—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0113	0.0455	CbGbCtD
Montelukast—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0108	0.0434	CbGbCtD
Montelukast—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00565	0.0227	CbGbCtD
Montelukast—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00534	0.0214	CbGbCtD
Montelukast—CYSLTR1—respiratory system—chronic obstructive pulmonary disease	0.00133	0.132	CbGeAlD
Montelukast—CYSLTR1—bronchus—chronic obstructive pulmonary disease	0.0011	0.109	CbGeAlD
Montelukast—CYSLTR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00107	0.106	CbGeAlD
Montelukast—ALOX5—respiratory system—chronic obstructive pulmonary disease	0.000807	0.08	CbGeAlD
Montelukast—ALOX5—connective tissue—chronic obstructive pulmonary disease	0.00071	0.0705	CbGeAlD
Montelukast—CYSLTR1—lung—chronic obstructive pulmonary disease	0.000708	0.0702	CbGeAlD
Montelukast—ALOX5—bronchus—chronic obstructive pulmonary disease	0.000664	0.0659	CbGeAlD
Montelukast—ALOX5—smooth muscle tissue—chronic obstructive pulmonary disease	0.00065	0.0645	CbGeAlD
Montelukast—SLCO2B1—respiratory system—chronic obstructive pulmonary disease	0.000621	0.0616	CbGeAlD
Montelukast—ALOX5—lung—chronic obstructive pulmonary disease	0.000428	0.0425	CbGeAlD
Montelukast—CYP2A6—lung—chronic obstructive pulmonary disease	0.000378	0.0375	CbGeAlD
Montelukast—SLCO2B1—lung—chronic obstructive pulmonary disease	0.00033	0.0327	CbGeAlD
Montelukast—PTGS1—respiratory system—chronic obstructive pulmonary disease	0.000324	0.0321	CbGeAlD
Montelukast—PTGS1—connective tissue—chronic obstructive pulmonary disease	0.000285	0.0283	CbGeAlD
Montelukast—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000261	0.0259	CbGeAlD
Montelukast—PTGS1—trachea—chronic obstructive pulmonary disease	0.000239	0.0237	CbGeAlD
Montelukast—Epistaxis—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00254	CcSEcCtD
Montelukast—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000218	0.00253	CcSEcCtD
Montelukast—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00252	CcSEcCtD
Montelukast—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00252	CcSEcCtD
Montelukast—Sinusitis—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00252	CcSEcCtD
Montelukast—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000216	0.00252	CcSEcCtD
Montelukast—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000216	0.00251	CcSEcCtD
Montelukast—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.00251	CcSEcCtD
Montelukast—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00251	CcSEcCtD
Montelukast—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00251	CcSEcCtD
Montelukast—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000213	0.00248	CcSEcCtD
Montelukast—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00021	0.00245	CcSEcCtD
Montelukast—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000209	0.00244	CcSEcCtD
Montelukast—Rhinitis—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00242	CcSEcCtD
Montelukast—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000207	0.00241	CcSEcCtD
Montelukast—Hypoaesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.0024	CcSEcCtD
Montelukast—Pharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.0024	CcSEcCtD
Montelukast—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000205	0.00239	CcSEcCtD
Montelukast—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00238	CcSEcCtD
Montelukast—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000204	0.00237	CcSEcCtD
Montelukast—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.00237	CcSEcCtD
Montelukast—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00237	CcSEcCtD
Montelukast—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000204	0.00237	CcSEcCtD
Montelukast—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000203	0.00237	CcSEcCtD
Montelukast—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00237	CcSEcCtD
Montelukast—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000202	0.00235	CcSEcCtD
Montelukast—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000202	0.00235	CcSEcCtD
Montelukast—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000201	0.00234	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.0002	0.00233	CcSEcCtD
Montelukast—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.00231	CcSEcCtD
Montelukast—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000198	0.00231	CcSEcCtD
Montelukast—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.0023	CcSEcCtD
Montelukast—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000198	0.0023	CcSEcCtD
Montelukast—Contusion—Prednisone—chronic obstructive pulmonary disease	0.000197	0.0023	CcSEcCtD
Montelukast—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000195	0.00227	CcSEcCtD
Montelukast—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000194	0.00226	CcSEcCtD
Montelukast—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000194	0.00225	CcSEcCtD
Montelukast—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000193	0.00225	CcSEcCtD
Montelukast—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000192	0.00224	CcSEcCtD
Montelukast—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00224	CcSEcCtD
Montelukast—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000192	0.00224	CcSEcCtD
Montelukast—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.00224	CcSEcCtD
Montelukast—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000192	0.00224	CcSEcCtD
Montelukast—Viral infection—Prednisone—chronic obstructive pulmonary disease	0.00019	0.00222	CcSEcCtD
Montelukast—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000189	0.00221	CcSEcCtD
Montelukast—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000188	0.00219	CcSEcCtD
Montelukast—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00218	CcSEcCtD
Montelukast—Injury—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.00218	CcSEcCtD
Montelukast—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00217	CcSEcCtD
Montelukast—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000185	0.00216	CcSEcCtD
Montelukast—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000184	0.00214	CcSEcCtD
Montelukast—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.00214	CcSEcCtD
Montelukast—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000183	0.00213	CcSEcCtD
Montelukast—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.00211	CcSEcCtD
Montelukast—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00018	0.0021	CcSEcCtD
Montelukast—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000179	0.00208	CcSEcCtD
Montelukast—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.00208	CcSEcCtD
Montelukast—Vasculitis—Prednisone—chronic obstructive pulmonary disease	0.000176	0.00205	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000176	0.00205	CcSEcCtD
Montelukast—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000176	0.00204	CcSEcCtD
Montelukast—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.00204	CcSEcCtD
Montelukast—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000175	0.00203	CcSEcCtD
Montelukast—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00203	CcSEcCtD
Montelukast—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00203	CcSEcCtD
Montelukast—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000174	0.00202	CcSEcCtD
Montelukast—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00202	CcSEcCtD
Montelukast—PTGS1—lung—chronic obstructive pulmonary disease	0.000172	0.0171	CbGeAlD
Montelukast—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.00017	0.00198	CcSEcCtD
Montelukast—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00197	CcSEcCtD
Montelukast—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000169	0.00197	CcSEcCtD
Montelukast—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.00197	CcSEcCtD
Montelukast—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000168	0.00195	CcSEcCtD
Montelukast—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000167	0.00194	CcSEcCtD
Montelukast—Cough—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00194	CcSEcCtD
Montelukast—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00194	CcSEcCtD
Montelukast—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.00193	CcSEcCtD
Montelukast—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00192	CcSEcCtD
Montelukast—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000163	0.0019	CcSEcCtD
Montelukast—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.00189	CcSEcCtD
Montelukast—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000163	0.00189	CcSEcCtD
Montelukast—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000163	0.00189	CcSEcCtD
Montelukast—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.00189	CcSEcCtD
Montelukast—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00189	CcSEcCtD
Montelukast—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00189	CcSEcCtD
Montelukast—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000162	0.00189	CcSEcCtD
Montelukast—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000162	0.00189	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00188	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00188	CcSEcCtD
Montelukast—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000161	0.00188	CcSEcCtD
Montelukast—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00186	CcSEcCtD
Montelukast—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000158	0.00184	CcSEcCtD
Montelukast—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.00183	CcSEcCtD
Montelukast—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000156	0.00182	CcSEcCtD
Montelukast—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.00182	CcSEcCtD
Montelukast—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000156	0.00182	CcSEcCtD
Montelukast—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.00182	CcSEcCtD
Montelukast—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.0018	CcSEcCtD
Montelukast—Infection—Formoterol—chronic obstructive pulmonary disease	0.000155	0.0018	CcSEcCtD
Montelukast—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00179	CcSEcCtD
Montelukast—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00179	CcSEcCtD
Montelukast—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000153	0.00179	CcSEcCtD
Montelukast—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00178	CcSEcCtD
Montelukast—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.00178	CcSEcCtD
Montelukast—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000153	0.00178	CcSEcCtD
Montelukast—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000153	0.00178	CcSEcCtD
Montelukast—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000151	0.00176	CcSEcCtD
Montelukast—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000151	0.00176	CcSEcCtD
Montelukast—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000151	0.00176	CcSEcCtD
Montelukast—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00175	CcSEcCtD
Montelukast—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00171	CcSEcCtD
Montelukast—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00171	CcSEcCtD
Montelukast—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.0017	CcSEcCtD
Montelukast—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.0017	CcSEcCtD
Montelukast—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000145	0.00169	CcSEcCtD
Montelukast—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.00168	CcSEcCtD
Montelukast—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.00167	CcSEcCtD
Montelukast—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000142	0.00166	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000142	0.00165	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000142	0.00165	CcSEcCtD
Montelukast—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.00164	CcSEcCtD
Montelukast—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000141	0.00164	CcSEcCtD
Montelukast—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00014	0.00163	CcSEcCtD
Montelukast—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000139	0.00161	CcSEcCtD
Montelukast—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.00161	CcSEcCtD
Montelukast—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.0016	CcSEcCtD
Montelukast—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000137	0.0016	CcSEcCtD
Montelukast—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000137	0.00159	CcSEcCtD
Montelukast—Injury—Prednisone—chronic obstructive pulmonary disease	0.000136	0.00158	CcSEcCtD
Montelukast—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000135	0.00158	CcSEcCtD
Montelukast—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000135	0.00157	CcSEcCtD
Montelukast—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.00157	CcSEcCtD
Montelukast—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000134	0.00157	CcSEcCtD
Montelukast—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.00157	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.00156	CcSEcCtD
Montelukast—Pain—Formoterol—chronic obstructive pulmonary disease	0.000133	0.00155	CcSEcCtD
Montelukast—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000133	0.00155	CcSEcCtD
Montelukast—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.00155	CcSEcCtD
Montelukast—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.00154	CcSEcCtD
Montelukast—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000131	0.00152	CcSEcCtD
Montelukast—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00013	0.00152	CcSEcCtD
Montelukast—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.00151	CcSEcCtD
Montelukast—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.00151	CcSEcCtD
Montelukast—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000129	0.0015	CcSEcCtD
Montelukast—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000129	0.0015	CcSEcCtD
Montelukast—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000129	0.0015	CcSEcCtD
Montelukast—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000128	0.00149	CcSEcCtD
Montelukast—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000128	0.00149	CcSEcCtD
Montelukast—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.00148	CcSEcCtD
Montelukast—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000128	0.00148	CcSEcCtD
Montelukast—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.00148	CcSEcCtD
Montelukast—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.00148	CcSEcCtD
Montelukast—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.00147	CcSEcCtD
Montelukast—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.00144	CcSEcCtD
Montelukast—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000124	0.00144	CcSEcCtD
Montelukast—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000123	0.00144	CcSEcCtD
Montelukast—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000123	0.00144	CcSEcCtD
Montelukast—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.00144	CcSEcCtD
Montelukast—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.00144	CcSEcCtD
Montelukast—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000123	0.00143	CcSEcCtD
Montelukast—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000122	0.00142	CcSEcCtD
Montelukast—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000122	0.00142	CcSEcCtD
Montelukast—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000122	0.00142	CcSEcCtD
Montelukast—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000121	0.00141	CcSEcCtD
Montelukast—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.0014	CcSEcCtD
Montelukast—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00139	CcSEcCtD
Montelukast—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.00136	CcSEcCtD
Montelukast—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.00136	CcSEcCtD
Montelukast—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.00136	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000116	0.00389	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000115	0.00387	CbGpPWpGaD
Montelukast—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000115	0.00386	CbGpPWpGaD
Montelukast—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000115	0.00134	CcSEcCtD
Montelukast—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000115	0.00134	CcSEcCtD
Montelukast—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000115	0.00134	CcSEcCtD
Montelukast—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.0013	CcSEcCtD
Montelukast—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000112	0.0013	CcSEcCtD
Montelukast—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00011	0.0037	CbGpPWpGaD
Montelukast—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00011	0.00128	CcSEcCtD
Montelukast—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.00128	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00128	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000109	0.00366	CbGpPWpGaD
Montelukast—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.00365	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000109	0.00364	CbGpPWpGaD
Montelukast—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000108	0.00126	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	0.000108	0.00363	CbGpPWpGaD
Montelukast—CYP2A6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000108	0.0036	CbGpPWpGaD
Montelukast—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000107	0.00124	CcSEcCtD
Montelukast—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000107	0.00124	CcSEcCtD
Montelukast—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00123	CcSEcCtD
Montelukast—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.00123	CcSEcCtD
Montelukast—CYP2C8—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000105	0.00351	CbGpPWpGaD
Montelukast—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00351	CbGpPWpGaD
Montelukast—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.00121	CcSEcCtD
Montelukast—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000103	0.0012	CcSEcCtD
Montelukast—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000103	0.0012	CcSEcCtD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000102	0.00343	CbGpPWpGaD
Montelukast—CYP2C8—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000101	0.00339	CbGpPWpGaD
Montelukast—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.00117	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	9.96e-05	0.00334	CbGpPWpGaD
Montelukast—Vomiting—Arformoterol—chronic obstructive pulmonary disease	9.91e-05	0.00115	CcSEcCtD
Montelukast—Vomiting—Formoterol—chronic obstructive pulmonary disease	9.91e-05	0.00115	CcSEcCtD
Montelukast—Rash—Formoterol—chronic obstructive pulmonary disease	9.83e-05	0.00114	CcSEcCtD
Montelukast—Rash—Arformoterol—chronic obstructive pulmonary disease	9.83e-05	0.00114	CcSEcCtD
Montelukast—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	9.82e-05	0.00114	CcSEcCtD
Montelukast—Dermatitis—Formoterol—chronic obstructive pulmonary disease	9.82e-05	0.00114	CcSEcCtD
Montelukast—Headache—Arformoterol—chronic obstructive pulmonary disease	9.77e-05	0.00114	CcSEcCtD
Montelukast—Headache—Formoterol—chronic obstructive pulmonary disease	9.77e-05	0.00114	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	9.76e-05	0.00327	CbGpPWpGaD
Montelukast—Dizziness—Salbutamol—chronic obstructive pulmonary disease	9.74e-05	0.00113	CcSEcCtD
Montelukast—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	9.64e-05	0.00323	CbGpPWpGaD
Montelukast—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	9.62e-05	0.00323	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	9.57e-05	0.00321	CbGpPWpGaD
Montelukast—Angioedema—Prednisolone—chronic obstructive pulmonary disease	9.46e-05	0.0011	CcSEcCtD
Montelukast—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	9.43e-05	0.0011	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	9.36e-05	0.00314	CbGpPWpGaD
Montelukast—Vomiting—Salbutamol—chronic obstructive pulmonary disease	9.36e-05	0.00109	CcSEcCtD
Montelukast—PTGS1—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.34e-05	0.00313	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	9.29e-05	0.00312	CbGpPWpGaD
Montelukast—Rash—Salbutamol—chronic obstructive pulmonary disease	9.28e-05	0.00108	CcSEcCtD
Montelukast—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	9.28e-05	0.00108	CcSEcCtD
Montelukast—Nausea—Arformoterol—chronic obstructive pulmonary disease	9.26e-05	0.00108	CcSEcCtD
Montelukast—Nausea—Formoterol—chronic obstructive pulmonary disease	9.26e-05	0.00108	CcSEcCtD
Montelukast—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	9.25e-05	0.0031	CbGpPWpGaD
Montelukast—Headache—Salbutamol—chronic obstructive pulmonary disease	9.22e-05	0.00107	CcSEcCtD
Montelukast—ALOX5—Metabolism—APIP—chronic obstructive pulmonary disease	9.2e-05	0.00309	CbGpPWpGaD
Montelukast—Convulsion—Prednisolone—chronic obstructive pulmonary disease	8.97e-05	0.00104	CcSEcCtD
Montelukast—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.83e-05	0.00296	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	8.75e-05	0.00294	CbGpPWpGaD
Montelukast—Nausea—Salbutamol—chronic obstructive pulmonary disease	8.75e-05	0.00102	CcSEcCtD
Montelukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	8.66e-05	0.0029	CbGpPWpGaD
Montelukast—CYP2C8—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	8.61e-05	0.00289	CbGpPWpGaD
Montelukast—Hallucination—Prednisone—chronic obstructive pulmonary disease	8.59e-05	0.001	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	8.54e-05	0.00286	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	8.52e-05	0.00286	CbGpPWpGaD
Montelukast—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000988	CcSEcCtD
Montelukast—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	8.45e-05	0.000983	CcSEcCtD
Montelukast—Oedema—Prednisolone—chronic obstructive pulmonary disease	8.45e-05	0.000983	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	8.44e-05	0.00283	CbGpPWpGaD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	8.33e-05	0.00279	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	8.31e-05	0.00279	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	8.3e-05	0.00278	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	8.3e-05	0.00278	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	8.23e-05	0.00276	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.22e-05	0.00275	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	8.14e-05	0.00273	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.12e-05	0.00272	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	7.85e-05	0.00263	CbGpPWpGaD
Montelukast—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	7.8e-05	0.000908	CcSEcCtD
Montelukast—CYP2A6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.77e-05	0.0026	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.68e-05	0.00257	CbGpPWpGaD
Montelukast—Insomnia—Prednisolone—chronic obstructive pulmonary disease	7.64e-05	0.000889	CcSEcCtD
Montelukast—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	7.58e-05	0.000883	CcSEcCtD
Montelukast—Mental disorder—Prednisone—chronic obstructive pulmonary disease	7.57e-05	0.000881	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	7.52e-05	0.00252	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	7.49e-05	0.00251	CbGpPWpGaD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.44e-05	0.00249	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	7.43e-05	0.00249	CbGpPWpGaD
Montelukast—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.34e-05	0.00246	CbGpPWpGaD
Montelukast—Pain—Prednisolone—chronic obstructive pulmonary disease	7.22e-05	0.000841	CcSEcCtD
Montelukast—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	7.01e-05	0.00235	CbGpPWpGaD
Montelukast—Agitation—Prednisone—chronic obstructive pulmonary disease	6.91e-05	0.000805	CcSEcCtD
Montelukast—Angioedema—Prednisone—chronic obstructive pulmonary disease	6.87e-05	0.0008	CcSEcCtD
Montelukast—PTGS1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.83e-05	0.00229	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	6.8e-05	0.00228	CbGpPWpGaD
Montelukast—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	6.8e-05	0.00228	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.76e-05	0.00227	CbGpPWpGaD
Montelukast—Urticaria—Prednisolone—chronic obstructive pulmonary disease	6.71e-05	0.000781	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	6.58e-05	0.00221	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	6.56e-05	0.0022	CbGpPWpGaD
Montelukast—Convulsion—Prednisone—chronic obstructive pulmonary disease	6.51e-05	0.000759	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	6.5e-05	0.00218	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.46e-05	0.00216	CbGpPWpGaD
Montelukast—Arthralgia—Prednisone—chronic obstructive pulmonary disease	6.4e-05	0.000745	CcSEcCtD
Montelukast—Myalgia—Prednisone—chronic obstructive pulmonary disease	6.4e-05	0.000745	CcSEcCtD
Montelukast—Anxiety—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000743	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	6.36e-05	0.00074	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	6.34e-05	0.00212	CbGpPWpGaD
Montelukast—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	6.22e-05	0.000725	CcSEcCtD
Montelukast—CYP2A6—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	6.22e-05	0.00209	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	6.14e-05	0.00206	CbGpPWpGaD
Montelukast—Oedema—Prednisone—chronic obstructive pulmonary disease	6.14e-05	0.000715	CcSEcCtD
Montelukast—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	6.14e-05	0.000715	CcSEcCtD
Montelukast—ALOX5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.1e-05	0.00204	CbGpPWpGaD
Montelukast—Infection—Prednisone—chronic obstructive pulmonary disease	6.1e-05	0.00071	CcSEcCtD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.06e-05	0.00203	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	6.05e-05	0.00203	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	6.05e-05	0.00203	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.03e-05	0.00202	CbGpPWpGaD
Montelukast—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	6.02e-05	0.000701	CcSEcCtD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	5.98e-05	0.002	CbGpPWpGaD
Montelukast—Skin disorder—Prednisone—chronic obstructive pulmonary disease	5.96e-05	0.000694	CcSEcCtD
Montelukast—ALOX5—Metabolism—GC—chronic obstructive pulmonary disease	5.93e-05	0.00199	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	5.77e-05	0.00194	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.77e-05	0.00194	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	5.76e-05	0.00193	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.69e-05	0.00191	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	5.64e-05	0.00189	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	5.62e-05	0.00189	CbGpPWpGaD
Montelukast—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	5.59e-05	0.000651	CcSEcCtD
Montelukast—Dizziness—Prednisolone—chronic obstructive pulmonary disease	5.58e-05	0.00065	CcSEcCtD
Montelukast—Insomnia—Prednisone—chronic obstructive pulmonary disease	5.55e-05	0.000646	CcSEcCtD
Montelukast—ALOX5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.51e-05	0.00185	CbGpPWpGaD
Montelukast—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	5.51e-05	0.000642	CcSEcCtD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	5.5e-05	0.00184	CbGpPWpGaD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	5.42e-05	0.00182	CbGpPWpGaD
Montelukast—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	5.4e-05	0.000629	CcSEcCtD
Montelukast—CYP2A6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.38e-05	0.00181	CbGpPWpGaD
Montelukast—Rash—Prednisolone—chronic obstructive pulmonary disease	5.32e-05	0.00062	CcSEcCtD
Montelukast—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	5.32e-05	0.000619	CcSEcCtD
Montelukast—CYP2C8—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.31e-05	0.00178	CbGpPWpGaD
Montelukast—Fatigue—Prednisone—chronic obstructive pulmonary disease	5.29e-05	0.000616	CcSEcCtD
Montelukast—Headache—Prednisolone—chronic obstructive pulmonary disease	5.29e-05	0.000616	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.27e-05	0.00177	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.25e-05	0.00176	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.23e-05	0.00175	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	5.21e-05	0.00175	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	5.19e-05	0.00174	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	5.02e-05	0.000584	CcSEcCtD
Montelukast—Nausea—Prednisolone—chronic obstructive pulmonary disease	5.02e-05	0.000584	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.98e-05	0.00167	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.96e-05	0.00166	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.95e-05	0.00166	CbGpPWpGaD
Montelukast—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	4.94e-05	0.00166	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.91e-05	0.00165	CbGpPWpGaD
Montelukast—Urticaria—Prednisone—chronic obstructive pulmonary disease	4.88e-05	0.000568	CcSEcCtD
Montelukast—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	4.85e-05	0.000565	CcSEcCtD
Montelukast—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	4.85e-05	0.000565	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.7e-05	0.00158	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	4.69e-05	0.00157	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.69e-05	0.00157	CbGpPWpGaD
Montelukast—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	4.52e-05	0.000526	CcSEcCtD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	4.46e-05	0.00149	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.41e-05	0.00148	CbGpPWpGaD
Montelukast—Asthenia—Prednisone—chronic obstructive pulmonary disease	4.4e-05	0.000513	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.39e-05	0.00147	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	4.39e-05	0.00147	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.35e-05	0.00146	CbGpPWpGaD
Montelukast—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.34e-05	0.000506	CcSEcCtD
Montelukast—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.32e-05	0.00145	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.27e-05	0.00143	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.27e-05	0.00143	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.2e-05	0.00141	CbGpPWpGaD
Montelukast—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.2e-05	0.000489	CcSEcCtD
Montelukast—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.06e-05	0.000473	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.02e-05	0.00135	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.02e-05	0.00135	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	4e-05	0.00134	CbGpPWpGaD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	3.99e-05	0.00134	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—APIP—chronic obstructive pulmonary disease	3.99e-05	0.00134	CbGpPWpGaD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	3.94e-05	0.00132	CbGpPWpGaD
Montelukast—Vomiting—Prednisone—chronic obstructive pulmonary disease	3.9e-05	0.000454	CcSEcCtD
Montelukast—Rash—Prednisone—chronic obstructive pulmonary disease	3.87e-05	0.000451	CcSEcCtD
Montelukast—Dermatitis—Prednisone—chronic obstructive pulmonary disease	3.87e-05	0.00045	CcSEcCtD
Montelukast—Headache—Prednisone—chronic obstructive pulmonary disease	3.84e-05	0.000448	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.81e-05	0.00128	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—APIP—chronic obstructive pulmonary disease	3.77e-05	0.00127	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.73e-05	0.00125	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.68e-05	0.00123	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.67e-05	0.00123	CbGpPWpGaD
Montelukast—Nausea—Prednisone—chronic obstructive pulmonary disease	3.65e-05	0.000424	CcSEcCtD
Montelukast—CYP2C8—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.63e-05	0.00122	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.59e-05	0.0012	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.54e-05	0.00119	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	3.4e-05	0.00114	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.38e-05	0.00113	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.34e-05	0.00112	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.33e-05	0.00112	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.24e-05	0.00109	CbGpPWpGaD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.24e-05	0.00109	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.2e-05	0.00107	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GCLC—chronic obstructive pulmonary disease	3.2e-05	0.00107	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.16e-05	0.00106	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.04e-05	0.00102	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.99e-05	0.001	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.99e-05	0.001	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.95e-05	0.00099	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.94e-05	0.000985	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CTGF—chronic obstructive pulmonary disease	2.92e-05	0.00098	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	2.85e-05	0.000955	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.85e-05	0.000954	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.82e-05	0.000944	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.75e-05	0.000922	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	2.75e-05	0.000921	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.73e-05	0.000916	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.71e-05	0.00091	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.69e-05	0.000903	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.64e-05	0.000886	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.64e-05	0.000885	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.62e-05	0.000879	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.61e-05	0.000874	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	2.58e-05	0.000864	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.57e-05	0.000862	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GC—chronic obstructive pulmonary disease	2.57e-05	0.000862	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.52e-05	0.000845	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.5e-05	0.000838	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GC—chronic obstructive pulmonary disease	2.43e-05	0.000815	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.39e-05	0.000802	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.37e-05	0.000794	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.33e-05	0.000783	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	2.3e-05	0.000771	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.27e-05	0.000761	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.26e-05	0.000758	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.25e-05	0.000755	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.25e-05	0.000753	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.21e-05	0.000743	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	2.1e-05	0.000703	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.06e-05	0.000692	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.06e-05	0.000691	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.05e-05	0.000686	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.97e-05	0.000662	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.97e-05	0.000661	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.96e-05	0.000656	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.95e-05	0.000653	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.9e-05	0.000639	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.84e-05	0.000616	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.83e-05	0.000614	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.81e-05	0.000608	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.79e-05	0.0006	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.72e-05	0.000577	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.71e-05	0.000573	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.7e-05	0.000569	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.69e-05	0.000568	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	1.66e-05	0.000557	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.54e-05	0.000518	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.51e-05	0.000505	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.5e-05	0.000502	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.44e-05	0.000482	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.4e-05	0.000471	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.39e-05	0.000466	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.39e-05	0.000466	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.38e-05	0.000464	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.38e-05	0.000462	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.37e-05	0.00046	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.35e-05	0.000453	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ALB—chronic obstructive pulmonary disease	1.33e-05	0.000446	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.33e-05	0.000445	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.31e-05	0.00044	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.29e-05	0.000434	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—NOS3—chronic obstructive pulmonary disease	1.27e-05	0.000427	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.27e-05	0.000425	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.26e-05	0.000421	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.23e-05	0.000413	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.22e-05	0.000408	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.2e-05	0.000402	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.17e-05	0.000391	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.16e-05	0.000388	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.1e-05	0.00037	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.1e-05	0.000369	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1e-05	0.000336	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.89e-06	0.000332	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.74e-06	0.000327	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.6e-06	0.000322	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.21e-06	0.000309	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.17e-06	0.000307	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.08e-06	0.000305	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.07e-06	0.000304	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.07e-06	0.000304	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	8.97e-06	0.000301	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.95e-06	0.0003	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	8.92e-06	0.000299	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.9e-06	0.000298	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.48e-06	0.000284	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.46e-06	0.000284	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.36e-06	0.00028	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.29e-06	0.000278	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	8.19e-06	0.000274	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.02e-06	0.000269	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.54e-06	0.000253	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.47e-06	0.000251	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.39e-06	0.000248	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	7.3e-06	0.000245	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.84e-06	0.000229	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.81e-06	0.000228	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	6.66e-06	0.000223	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.29e-06	0.000211	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.2e-06	0.000208	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.14e-06	0.000206	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.78e-06	0.000194	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	5.77e-06	0.000193	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.52e-06	0.000185	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.48e-06	0.000184	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ALB—chronic obstructive pulmonary disease	5.45e-06	0.000183	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.22e-06	0.000175	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.12e-06	0.000172	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.05e-06	0.000169	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.87e-06	0.000163	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.81e-06	0.000161	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.7e-06	0.000158	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.46e-06	0.00015	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.39e-06	0.000147	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.05e-06	0.000136	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.72e-06	0.000125	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	3.56e-06	0.000119	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.38e-06	0.000113	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.33e-06	0.000112	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.1e-06	0.000104	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.03e-06	0.000102	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.94e-06	9.86e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.9e-06	9.72e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2e-06	6.7e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.91e-06	6.41e-05	CbGpPWpGaD
